Oruka Therapeutics officer plans $50.6K stock sale

An Oruka Therapeutics officer filed a Rule 144 notice to sell 533 shares from recently acquired RSUs, alongside prior 10b5-1 plan sales.

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. (ORKA) has an officer, Arjun Agarwal, filing a notice under Rule 144 for a planned sale of common stock. The notice covers 533 shares, with an aggregate market value of $50,613.68 and cites 66,209,699 shares outstanding, with sales expected around September 21, 2026. The shares come from Restricted Stock Units acquired on September 14, 2026. The filing also lists several prior sales over the past three months, including transactions made pursuant to a Rule 10b5-1 trading plan.

Key Figures

Shares to be sold under Rule 144: 533 shares Aggregate market value of planned sale: $50,613.68 Shares outstanding: 66,209,699 shares +5 more

8 metrics

Shares to be sold under Rule 144 533 shares Planned sale of Oruka Therapeutics common stock by an officer

Aggregate market value of planned sale $50,613.68 Value of 533 shares of Oruka Therapeutics common stock covered by the notice

Shares outstanding 66,209,699 shares Common stock outstanding for Oruka Therapeutics as referenced in the notice

Approximate sale date September 21, 2026 Expected date of the Rule 144 sale on NASDAQ

Acquisition date of RSUs September 14, 2026 Restricted Stock Units from which the 533 shares will be sold

Past sale on September 15, 2026 560 shares for $53,597.60 Common stock sale by Arjun Agarwal during the past three months

Past 10b5-1 sale on September 11, 2026 9,459 shares for $872,413.00 10b5-1 Sales of Oruka Therapeutics common stock

Past 10b5-1 sale on August 13, 2026 10,000 shares for $1,066,571.87 10b5-1 Sales of Oruka Therapeutics common stock

Key Terms

Rule 144, Restricted Stock Units, 10b5-1 Sales

3 terms

Rule 144 regulatory

"Name of Person for Whose Account the Securities are To Be Sold | Arjun Agarwal See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Units financial

"Common | 09/14/2026 | Restricted Stock Units | Issuer"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

10b5-1 Sales regulatory

"10b5-1 Sales for ARJUN AGARWAL 855 Oak Grove Avenue Suite 100 Menlo Park CA 94025 | Common"

10b5-1 sales are pre-arranged stock-trading plans that let company insiders automatically buy or sell shares according to a fixed schedule or formula, even if they later learn confidential information. Think of it as setting up an automatic thermostat for trades: it creates a clear, documented path that can protect insiders from insider-trading accusations and gives investors a signal about predictable insider activity—though it can also simply be a way for insiders to diversify or raise cash.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for ORKA disclose about planned share sales?

The Form 144 notice states that an officer of Oruka Therapeutics plans to sell 533 shares of common stock with an aggregate market value of $50,613.68, with the sale expected around September 21, 2026 on NASDAQ.

How many Oruka Therapeutics (ORKA) shares are reported outstanding in this Form 144?

The filing reports that 66,209,699 shares of Oruka Therapeutics common stock were outstanding, providing a context figure relative to the 533 shares covered by the planned Rule 144 sale.

What is the source and acquisition date of the ORKA shares to be sold?

The shares covered by the notice originate from Restricted Stock Units acquired on September 14, 2026 from the issuer, Oruka Therapeutics. The payment for these RSUs is listed as N/A in the filing.

Which broker is named for executing the ORKA Form 144 sale?

The planned sale of Oruka Therapeutics shares is listed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

What prior Oruka Therapeutics (ORKA) share sales by Arjun Agarwal are reported?

The filing lists past three-month sales including 560 shares for $53,597.60 on September 15, 2026, plus additional common stock sales on June 22, July 13, August 13, and September 11, 2026, some noted as 10b5-1 Sales.

Are any of the reported ORKA share sales under a Rule 10b5-1 trading plan?

Yes. The filing labels several transactions as 10b5-1 Sales for Arjun Agarwal, including common stock sales on June 22, July 13, August 13, and September 11, 2026, indicating they were executed under a pre-arranged trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/21/2026 - 04:28 PM Accepted by SEC EDGAR 09/21/2026 - 04:27 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002033974
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Oruka Therapeutics, Inc.
SEC File Number	000-22873
Address of Issuer	855 Oak Grove Avenue Suite 100 Menlo Park CALIFORNIA 94025
Phone	6506067910
Name of Person for Whose Account the Securities are To Be Sold	Arjun Agarwal
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	533	50613.68	66209699	09/21/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/14/2026	Restricted Stock Units	Issuer			533	09/14/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
ARJUN AGARWAL 855 Oak Grove Avenue Suite 100 Menlo Park CA 94025	Common	09/15/2026	560	53597.60
10b5-1 Sales for ARJUN AGARWAL 855 Oak Grove Avenue Suite 100 Menlo Park CA 94025	Common	09/11/2026	9459	872413.00
10b5-1 Sales for ARJUN AGARWAL 855 Oak Grove Avenue Suite 100 Menlo Park CA 94025	Common	08/13/2026	10000	1066571.87
10b5-1 Sales for ARJUN AGARWAL 855 Oak Grove Avenue Suite 100 Menlo Park CA 94025	Common	07/13/2026	9999	846180.51
10b5-1 Sales for ARJUN AGARWAL 855 Oak Grove Avenue Suite 100 Menlo Park CA 94025	Common	06/22/2026	1587	128468.24

144: Remarks and Signature

Remarks
Date of Notice	09/21/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/11/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Arjun Agarwal
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)